ABOUT US

I'm a title. Click here to add your own text and edit me.

HH Logo 480PX.png
NEWS

Hyperbolic is working with a variety of clients and partners. This page reflects some of the notable up to date news and events related to those companies.

NEWS UPDATES  2022

HH Logo 480PX.png

The Chief Scientific Advisor at FAKnostics has recently published that Stage-1 colorectal cancer patients with high FAK have a significantly increased recurrence and lower overall survival prognosis. This demonstrates in a peer-reviewed setting the prognostic value of the pathology FAKnosTest. The company is continuing the work with the Institute of Digital Medicine at the Augsburg University Clinic to optimize and digitize the FAKnosTest for high-throughput digital pathology applications. www.faknostics.com 

HH Logo 480PX.png

NX VENTURES. Hyperbolic Holdings co-founded NX Ventures with Zaluvida Holdings, a privately-owned group focused on natural products development for nutraceutical, cosmeceutical and animal health markets. NX Ventures is a platform designed to bring 3rd party innovative science-based products from early stage to commercial stage by utilizing a variety of existing service companies held by the group, namely: Compound Discovery & Optimization (NEEM), Formulation & Product Development (INQPHARM), Clinical Trials & Regulatory Optimization (A&R), Financial Structuring & Distribution (Hyperbolic Holdings). The business model consists in taking active positions into start-ups with a combination of cash investments and in-kind development work realized by our service companies. Currently we have a pipeline of potential candidates in weight loss, liver health, eye and brain health as well as in animal gut health.

NEWS 2021

HH Logo 480PX.png
HH Logo 480PX.png
HH Logo 480PX.png
HH Logo 480PX.png
HH Logo 480PX.png

FAUNA SYSTEMS: Hyperbolic recently co-founded Fauna Systems Inc to commercialize xenobot technologies from the labs of Dr Mike Levin at Tufts University, Dr Josh Bongard from University of Vermont, and their joint Institute for Computational Design of Organisms (ICDO). Xenobots are living robots manufactured from living cells that can be programmed and optimized for certain functions. They are implemented based on the new paradigm-changing theory of morphological organization of multi-cellular systems being developed by Levin and Bongard. We intend to roll out a variety of xenobot applications to solve environmental, technological, computational and medical problems.



FAKNostics, a Hyperbolic portfolio company, has recently obtained a significant STTR grant for $2.3M over 3 years to develop our Melanoma program till IND. This grant will also benefit our colleagues at the University of Arizona who are helping to develop certain aspects of the melanoma project.
FAKNostics is collaborating with the Institute for Digital Medicine at the Augsburg University Clinic to further optimize our Colorectal and rectal cancer pathology prognostic test (FAKnosTest) based on automated pattern recognition and machine learning techniques.



INSULAB, a Hyperbolic portfolio company, is preparing a clinical trial with the Moscow Clinical Research Institute to perform efficacy tests of its automated insulin-provision algorithm for a closed loop artificial pancreas context. The initial cohort will consist of Type 1 diabetic patients.



FBB BIOMED, a Hyperbolic portfolio company, has recently filed a variety of patents on its proprietary differential gene expression prognostic test of disease severity, for a variety of auto-immune and neurological diseases.



RMS, a Hyperbolic portfolio company, has recently obtained financing from Mission:Cure Capital, a foundation that finances projects aimed at curing pancreatitis. This financing helps bring RMS closer to the goal of filling an IND in the first half of 2022.

HH Logo 480PX.png

Our dialysis client has recently obtained a 510K FDA approval for its small but powerful, ergonomic and hygenic machine. This opens the door for expansion into the US home dialysis market that is expacted to grow significantly in the years to come, with The Center for Medicare and Medicaid Services targeting a 50% home dialisys adoption by 2025. The government and payor support for home dialysis has significantly increased thanks to advances in technology, such as at our client, and because of COVID-overburdened health facilities. The company has a CE Mark and has started deploying the machines in the UK, Holland and Belgium. Hyperbolic continues to help our client with business development. 

HH Logo 480PX.png

Our client that developed a fiber-based sugar absorbing supplement and ingredient has been accepted to the prestigious Pepsico accelerator in January 2021. It has recently improved the efficacy of the product with significantly higher absorbtion rates. We are helping this client with business and financing strategy as well as with the set-up of a clinical trial. 

HH Logo 480PX.png

Our client that invented a fast-acting hemostat gel has successfully started generating revenues by selling into the US veterinary surgery market. It also almost finished raising its Series A, which now propels it to the next stage of working to complete the Class 2 device designation for emergency and military use this year. This step is crucial for the hemostat to gain the Class 3 wide-use designation next year. We continue to work with our client on business development.

HH Logo 480PX.png

The collagen nano-fiber technology has already demonstrated high efficiency in treating lymphodemas that occur after breast cancer surgery or after injuries to the lymphatic system. It has gained a CE Mark previously thanks to those results. Given the relatively high occurrence of lymphodema after breast cancer surgery, one of the goals of our client is to bring this technology as a preventative treatment performed at the time of such cancer surgery. Our client has just launched a multi-center preventative trial of this kind, and we continue to help them with financing strategy.   

NEWS 2020

HH Logo 480PX.png

Hyperbolic became involved with this cutting-edge qPCR technology company, with a view to assisting them to open new markets. This company developed one of the most effective and precise COVID-19 tests. It targets a highly conserved gene and is platform-independent. Since obtaining CE and EUA FDA approvals, the company has become a strong competitor to major brands. They are now selling millions of tests worldwide to labs in 80 different countries. Hyperbolic was instrumental in introducing a variety of private and government entities to facilitate this substantial increase in sales. Hyberbolic continues to open new markets and introduce new clients from our network. 

HH Logo 480PX.png

Hyperbolic is working with an oncology platform company, which continues to generate top quality data from its diagnostic and therapeutic trials . Most recently it obtained very competitive results for prognostication of responders to Check-Point Inhibitor therapies, in collaboration with one of the largest clinical cancer centres in the USA. Hyperbolic is actively assisting the company to prepare for license negotiations for some of its products as well as to set up a first-in human trials in Europe.

HH Logo 480PX.png

Hyberbolic was approached by this therapeutic company to complete due diligence on behalf of their potential investors. This helped to attract their lead investor for their Series A. Hyperbolic is now assisting them to build a strategic syndicate.   

HH Logo 480PX.png

Hyberbolic was attracted to this therapeutic company because of its strong in-vitro results for potential COVID- 19 anti-virals. Hyperbolic believes that antivirals for COVID will be potentially a bigger market than vaccines and actively works with the company to find strategic partners for that specific project

HH Logo 480PX.png

Hyperbolic has become a shareholder in a company that is developing a TAT pathway platform for a variety of infectious disease indications. The board decided to spin-off all preclinical non-HIV applications into a new entity and leave Phase-3 ready HIV TAT applications in the old entity. The new developments include COVID-19, TB and HSV. This will optimize the workflow, grant writing, capital raising and messaging. Hyperbolic is actively assisting the company with its business and fundraising strategy.

HH Logo 480PX.png

Hyperbolic has become a shareholder in a company that is developing a TAT pathway platform for a variety of infectious disease indications. The board decided to spin-off all preclinical non-HIV applications into a new entity and leave Phase-3 ready HIV TAT applications in the old entity. The new developments include COVID-19, TB and HSV. This will optimize the workflow, grant writing, capital raising and messaging. Hyperbolic is actively assisting the company with its business and fundraising strategy.

HH Logo 480PX.png

Hyperbolic is working with a novel oncology company that is developing a prognostic, a therapy and a companion diagnostic for cancers that have high metastatic risk. Hyperbolic is helping this company to prepare for its first financing round by advising on its intellectual property and licensing strategy.